At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 519 enrolled
Drug / intervention
iNO +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes
In Brief
A Phase 4 clinical trial evaluating iNO and iEPO for Heart Transplant Surgery and Lung Transplant Surgery. Completed, enrolled 519 participants across 1 site.
Detailed Summary
1\. to conduct a clinical investigation to determine if inhaled epoprostenol (Veletri®, iEPO) and inhaled nitric oxide (iNO) will have similar impact on outcomes in adult patients undergoing durable LVAD placement, heart transplantation, or lung transplantation 2. to conduct a cost-capture analysis on the expense each drug incurs per patient.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Transplant Surgery, Lung Transplant Surgery
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartMay 2017
Primary CompletionOct 2020
Study CompletionSep 2021
TodayJul 2026
First PostedMar 15, 2017
Enrollment StartMay 4, 2017
Primary CompletionOct 5, 2020
Study CompletionSep 5, 2021
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 9.3 years ago
Interventions
iNOdrug
Subject will receive inhaled Nitric Oxide in this intervention
iEPOdrug
Subject will receive inhaled Epoprostrenol in this intervention